Johnson & Johnson vs Merck
JNJ and MRK side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How JNJ and MRK compare
Johnson & Johnson is the larger company, worth 1.9 times as much as Merck ($671B against $356B).
On earnings, Johnson & Johnson is cheaper: it trades at 42.3× trailing earnings, against 116× for Merck.
Johnson & Johnson grew revenue faster over the last twelve months (7.8% versus 4.6% for Merck).
Johnson & Johnson keeps more of each dollar of sales as profit, with a net margin of 16.2% compared with 4.8% at Merck.
Both pay dividends: Johnson & Johnson yields 1.9% and Merck 2.4%.
Johnson & Johnson scores higher on the StockData Score (12 against 9 for Merck), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | JNJ | MRK |
|---|---|---|
| Size and price | ||
| Market cap | $671B | $356B |
| Share price | $278.70 | $144.46 |
| Change, 1 year | 42.2% | 55.5% |
| Change, 5 years | 75.1% | 82.5% |
| Beta (5Y) | −0.30 | −0.14 |
| Employees | 138K | 75K |
| StockData Score | ||
| Total score | 12 (better) | 9 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 0 |
| Performance score | 4 (better) | 3 |
| Health score | 3 | 3 |
| Dividend score | 2 | 3 (better) |
| Valuation | ||
| P/E | 42.3× (better) | 116× |
| P/S | 6.8× | 5.4× (better) |
| P/B | 8.2× (better) | 8.5× |
| EV/EBITDA | 26.0× | – |
| P/FCF | 32.6× | 22.2× (better) |
| PEG | 2.36 (better) | 13.70 |
| FCF yield | 3.1% | 4.5% (better) |
| Fair value | $150.10 | $42.50 |
| Margin of safety | −85.7% (better) | −240% |
| Growth | ||
| Revenue growth (TTM) | 7.8% (better) | 4.6% |
| Revenue growth, 5Y average | 2.7% | 9.4% (better) |
| Net income growth (TTM) | −35.9% (better) | −80.7% |
| EPS growth (TTM) | −36.4% (better) | −80.7% |
| EPS growth, 5Y average | 14.9% | 21.2% (better) |
| Profitability | ||
| Gross margin | 67.6% | 73.0% (better) |
| Net margin | 16.2% (better) | 4.8% |
| FCF margin | 20.7% | 24.1% (better) |
| Return on equity | 20.0% (better) | 7.0% |
| Financial health | ||
| Debt / equity | 0.55 (better) | 1.29 |
| Net debt / EBITDA | 1.02 | – |
| Current ratio | 1.02 | 1.32 (better) |
| Altman Z-score | 5.18 (better) | 3.71 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Dividend yield | 1.9% | 2.4% (better) |
| Payout ratio | – | 262% |
| Years of dividend growth | 16 (better) | 15 |
| Dividend growth, 5Y average | 5.2% | 5.8% (better) |
| Buyback yield | 1.2% | 1.2% (better) |
| Shareholder yield | 3.1% | 3.5% (better) |
| Ownership | ||
| Held by institutions | 74.8% | 80.3% |
| Held by insiders | 0.04% | 0.05% |
| Insider net buying, 12 months | −$154M | −$79.3M (better) |
| Superinvestors holding | 6 (better) | 4 |
| Short interest, % of float | 0.71% | 1.1% |
Go deeper
- JNJ stock overview
- JNJ income statement
- JNJ valuation and score
- MRK stock overview
- MRK income statement
- MRK valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.